Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Org 25935 add-on therapy for negative symptoms of schizophrenia
2006-003080-31Phase 2Completed
- Sponsor
- Organon & Co.
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Org 25935 add-on with Placebo add-on (2 arms). Primary endpoints: Change in negative symptoms (SANS total score, first 22 items) and Safety and tolerability of Org 25935. Started Oct 2006; status: completed.
02
Drugs
org 25935
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2006-003080-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003080-31.